Intranasal antihistamines and corticosteroids in the treatment of allergic rhinitis: a systematic review and meta-analysis protocol

Data de publicação: 01/11/2023 Data Ahead of Print: 02/11/2023

Autores da FMUP

• Bernardo Manuel De Sousa Pinto

  Autor

• Rafael José Monteiro Da Silva Vieira

  Autor

• António De Almeida E Sousa Cardoso Fernandes

  Autor

• Renato Ivo Ferreira Da Silva

  Autor

• André De Sousa Ferreira

  Autor

• João De Almeida Lopes Da Fonseca

  Autor

Participantes de fora da FMUP

• Brozek, J
• Louren?o Silva, N
• Gil Mata, S
• Bedbrook, A
• Klimek, L
• Zuberbier, T
• Schünemann, HJ
• Bousquet, J

Unidades de investigação

• Biomedicina

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

• Medicina da Comunidade, Informação e Decisão em Saúde

• RISE-Health

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

IntroductionIntranasal antihistamines and corticosteroids are some of the most frequently used drug classes in the treatment of allergic rhinitis. However, there is uncertainty as to whether effectiveness differences may exist among different intranasal specific medications. This systematic review aims to analyse and synthesise all evidence from randomised controlled trials (RCTs) on the effectiveness of intranasal antihistamines and corticosteroids in rhinitis nasal and ocular symptoms and in rhinoconjunctivitis-related quality-of-life.Methods and analysisWe will search four electronic bibliographic databases and three clinical trials databases for RCTs (1) assessing patients >= 12 years old with seasonal or perennial allergic rhinitis and (2) comparing the use of intranasal antihistamines or corticosteroids versus placebo. Assessed outcomes will include the Total Nasal Symptom Score (TNSS), the Total Ocular Symptom Score (TOSS) and the Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ). We will assess the methodological quality of included primary studies by using the Cochrane risk-of-bias tool. Certainty in the body of evidence for the analysed outcomes will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. We will perform a random-effects meta-analysis for each assessed medication and outcome, presenting results as pooled mean differences and standardised mean differences. Heterogeneity will be explored by sensitivity and subgroup analyses, considering (1) the risk of bias, (2) the follow-up period and (3) the drug dose.Ethics and disseminationEthical considerations will not be required. Results will be disseminated in a peer-review journal.PROSPERO registration numberCRD42023416573.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Keywords

• Immunology; Asthma; Allergy; Chronic airways disease